Effects of a Second-Generation Human Anti-ErbB2 ImmunoRNase on Trastuzumab-Resistant Tumors and Cardiac Cells

Protein Engineering, Design and Selection - United Kingdom
doi 10.1093/protein/gzu014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Oxford University Press (OUP)

Related search

Two Novel Human Anti-ErbB2 Immunoagents Are Active on Trastuzumab-Resistant Tumours

British Journal of Cancer
Cancer ResearchOncology
2010English

The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2013English

A Novel Toll-Like Receptor 9 Agonist Cooperates With Trastuzumab in Trastuzumab-Resistant Breast Tumors Through Multiple Mechanisms of Action

Clinical Cancer Research
Cancer ResearchOncology
2009English

Anti-Proliferative Effects of Evodiamine on Human Breast Cancer Cells

PLoS ONE
Multidisciplinary
2013English

Nectin-4 Cis-Interacts With ErbB2 and Its Trastuzumab-Resistant Splice Variants, Enhancing Their Activation and DNA Synthesis

Scientific Reports
Multidisciplinary
2019English

Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

Inhibitors of HSP90 Block P95-Her2 Signaling in Trastuzumab-Resistant Tumors and Suppress Their Growth

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Anti-Atherosclerotic Effects of Sirolimus on Human Vascular Smooth Muscle Cells

American Journal of Physiology - Heart and Circulatory Physiology
Cardiovascular MedicinePhysiologyCardiology
2007English

Anti-Igf-1r Monoclonal Antibody Inhibits the Carcinogenicity Activity of Acquired Trastuzumab-Resistant SKOV3

Journal of Ovarian Research
GynecologyOncologyObstetrics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy